Solid-phase synthetic route to multiple derivatives of a fundamental peptide unit

Article abstract of DOI:10.3390/molecules15074961

Amino acids are Nature's combinatorial building blocks. When substituted on both the amino and carboxyl sides they become the basic scaffold present in all peptides and proteins. We report a solid-phase synthetic route to large combinatorial variations of this fundamental scaffold, extending the variety of substituted biomimetic molecules available to successfully implement the Distributed Drug Discovery (D3) project. In a single solid-phase sequence, compatible with basic amine substituents, three-point variation is performed at the amino acid a-carbon and the amino and carboxyl functionalities.

Full text of DOI:10.3390/molecules15074961

Molecules 2010, 15, 4961-4983; doi:10.3390/molecules15074961
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Solid-Phase Synthetic Route to Multiple Derivatives of a
Fundamental Peptide Unit
William L. Scott 1,*, Ziniu Zhou 1, Paweł Zajdel 2, Maciej Pawłowski 2 and
Martin J. O’Donnell 1,*
1
Department of Chemistry and Chemical Biology, Indiana University-Purdue University
Indianapolis, 402 N. Blackford Street, Indianapolis, IN 46202, USA
2
Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street,
30-688 Kraków, Poland
* Authors to whom correspondence should be addressed; E-Mails: wscott@iupui.edu (W.L.S.);
modonnel@iupui.edu (M.J.O.).
Received: 7 June 2010; in revised form: 23 June 2010 / Accepted: 12 July 2010 /
Published: 20 July 2010
Abstract: Amino acids are Nature’s combinatorial building blocks. When substituted on
both the amino and carboxyl sides they become the basic scaffold present in all peptides
and proteins. We report a solid-phase synthetic route to large combinatorial variations of
this fundamental scaffold, extending the variety of substituted biomimetic molecules
available to successfully implement the Distributed Drug Discovery (D3) project. In a
single solid-phase sequence, compatible with basic amine substituents, three-point
variation is performed at the amino acid α-carbon and the amino and carboxyl
functionalities.
Keywords: Distributed Drug Discovery (D3); fundamental peptide scaffold; biomimetics;
solid-phase organic synthesis; combinatorial chemistry
Introduction
The Distributed Drug Discovery (D3) project seeks to simultaneously educate and innovate while
searching for drug leads for neglected diseases [1-6]. Central to this effort is the availability of simple,
inexpensive and reproducible synthetic procedures providing access to large numbers of biomimetic

Molecules 2010, 15
4962
molecules. To increase the diversity of molecule types available to D3 we decided to develop more
flexible synthetic routes to derivatives of the peptide unit 1, one of the most fundamental and
inherently biomimetic scaffolds in nature. There are many examples of drugs or drug leads based on
this scaffold. They arise from natural or unnatural amino acids modified at both the amino and
carboxylic acid functionalities. These include the recently approved drug lacosamide (Vimpat®, 1a) to
treat epilepsy [7]. Special cases of 1 are 2 and 3, in which R3 contains a basic amino group and n = 1 or
2. Compounds 3 have been shown to be selective binding agents for subclasses of 5-
hydroxytryptamine (5-HT, serotonin) receptors [8]. This paper reports a flexible solid-phase synthetic
route to many variations of R1, R2, and R3 on structures 2 and 3. It will be the basis for future synthetic
laboratories compatible with the D3 process.
Figure 1. Important molecules containing the fundamental peptide unit 1.
R4
OMe
R1
R1
O
O
R1
N
O
O
H
H
N
H
H
R3
N
N
N
Ph
R2
N
N
R2
N
R2
N
R3
n
H3C
N
n
H
H
H
H
O
O
O
O
1
1a
2
3
Compounds 1 can be readily synthesized on solid-phase using BAL type resins and naturally
occurring amino acids [9,10]. For more extensive sets of derivatives, unnatural amino acid side chains
R1 can be introduced during the course of the solid-phase synthesis utilizing the recently described
chemistry outlined in Scheme 1 [6].
Scheme 1. Synthetic route to amino- and carboxyl-substituted unnatural amino acids.
B
B
R3NH2
B
B
H
TMOF
B
H
N
N
N
R3
FmocGly
HBTU, DIEA
R3
FmocNH
R3
H
N
H N
2
NaCNBH3
HN
Piperidine
R3
O
O
O
O
O
Cl
4
5
6
7
8
Cl
Cl
MeO
O
Cl
B
H
R1-X
BTPP
R1
4
O
OMe
"BAL Aldehyde"
B
B
B
R1
O
R1
R1
H
O
H
N
N
N
N
R2
N
R3
R2
N
R3
+H3N
2) R2CO2H,
DIC, HOBt
R3
N
R3
1) DIEA
30% TFA
1 N HCl/THF
H
H
O
O
O
O
Cl
9
1
11
10
Cl
Compounds 3 are usually constructed from naturally occurring amino acids in which the amino
group is acylated with a variety of carboxylic acids and the carboxyl group is amidated with amines
containing an additional basic amino group. The solid-phase synthesis of 3 utilizes BAL-type linkers,
“lantern” technology, and either of two synthetic routes (Scheme 2, Path A or B). While Path A
provides a direct route to product, Path B (through intermediate 17) permits greater flexibility by
incorporation of many amines after attachment of the amino acid onto the BAL resin [11].

Molecules 2010, 15
4963
Scheme 2. Synthetic pathways A and B to compounds 3.
R4
R4
R4
O
R1
N
O
R1
N
R1
N
90% TFA
piperidine
H
N
N
N
N
N
N
R2
N
R2
N
H
R2COOH
FmocNH
n
n
n
H
n = 1,2
3
16
13
O
O
15
O
BOP, DIEA
Fmoc-AA-OH
DIC
H2N
R3
n
Path A [9]
H
O
= Lantern functionalized
with BAL type linker
R3
Reductive
amination
HN
12
n
14
Path B [11]
Fmoc-AA-OH
DIC
O
R1
R1
O
R1
TBAF
OH
piperidine
N
N
O
n
N
O
R2
N
R2
N
H
Si
FmocNH
Si
n
n
R2COOH
Ph
R4
H
Ph
R4
19
O
18
O
Ph
17
O
Ph
BOP, DIEA
MsCl, Py
R1
O
R1
N
O
R1
N
O
amine
OMs
90% TFA
H
N
N
N
N
N
R2
N
R2
N
R2
N
DMSO
n
n
n
H
H
H
n = 1,2
16
3
O
O
20
O
Results and Discussion
We sought to adapt the route shown in Scheme 1 to the synthesis of a more diverse set of
compounds 2 and 3, where R1 would possess both R and S configuration, not be restricted to naturally
occurring amino acid side chains, and R3 in 2 contained basic amine functionality that could be readily
varied. However, a key step in this synthesis would be the alkylation of intermediate 8 to 9 (Scheme
1), and any nucleophilic functionality present (such as the tertiary amines present in 3) would likely
lead to side reactions. Therefore, we decided to modify our chemistry to perform the alkylation on a
derivative of key intermediate imine 8 that would be compatible with this alkylation chemistry and
permit subsequent simple conversion to multiple derivatives 2 even if R3 contained nucleophilic sites.
Since it had already been shown that silyl protected intermediate 17 could be readily converted into 3
(Scheme 2), the silyl protected imine derivative 23 was chosen for this role (Scheme 3). It permitted
alkylation to 24 without side reactions. This provided access to many additional derivatives 2 after
deprotection of the silyl group (25 to 26), activation of the alcohol for displacement reactions (through
either the mesylate 27a or the more reactive iodide 27b) and displacement with a variety of amines.
Model studies to 2 were performed with four alkylating agents R1X: [R1 = CH2Ph, CH2CH=CH2;
(CH2)7CH3; CH2Ph-4-CF2-P(O)(OEt)2] (Scheme 3). The acylating agent (R2 = 4-NC-Ph), nucleophile
R3 and chain length were kept constant. In addition these initial studies, which focused on the
compatibility of the protected silyl alcohol with alkylation chemistry, utilized the alcohol activation
and amine incorporation procedures (via mesylate 27a) employed in the earlier lantern-based work
[11]. Products for this 11-step synthesis were obtained in moderate overall yields (Table 1). Structure
2d, which incorporates a stable, protected phosphotyrosine analog [6], gives a particular example of
the interesting types of molecules available by this route.

Molecules 2010, 15
4964
Scheme 3. Synthesis of multiply-substituted 2 where R3 contains a nucleophilic site.
H2N
O
"B" = BAL type linkers
Si
B
Ph
Ph
B
H
HN
O
Si
1) DMF-TMOF
2) NaBH3CN
Ph
O
Ph
21
4
Fmoc-Gly
HBTU, DIEA
B
B
B
H
H
R1
R1X, BTPP
N
O
N
O
N
O
Ar
N
Si
Ar
N
Si
FmocNH
Si
Ph
Ph
Ph
23
24
22
O
Ph
O
Ph
O
Ph
1) Piperidine
2) 2,3-dichloro-
benzaldehyde
1) 1N HCl-THF
2) R2COOH/HOBt/DIC
B
B
B
R1
O
R1
O
R1
MsCl/Pyr (to 27a)
O
TBAF
N
OH
N
O
N
X
R2
N
R2
N
H
Si
Ph
R2
N
H
or PPh3,
Imidazole,
I2 (to 27b)
H
26
25
O
O
Ph
O
N
27a: X = OMs
27b: X = I
Nu: (= R3)
B
R4
O
R1
O
R1
O
R1
N
H
N
H
TFA
R3
R3
N
N
R2
N
R2
N
H
or
R2
N
H
H
28
2
3
O
O
O
Table 1. Survey of alkylating agents with incorporation of a single amine.
O
R1
NH
N
Compound
R1
Yielda
26%
19%
29%
NH
O
2a-d
NC
2a
2b
2c
2d
-CH2Ph
-CH2CH=CH2
-(CH2)7CH3
F
F
O
P
OEt
OH
-CH2-Ph-4-CF2-P(O)(OH)(OEt) 18%
O
a Purified overall yields from 4
NH
2d
N
NH
O
NC
In this preliminary work a variety of by-products were formed during the alcohol to amine
transformation (26 to 28 via 27a, Scheme 3). To minimize side-reactions and provide an alternative
activation procedure, we developed a modified route through iodide intermediate 27b. A direct
comparison of these two routes gave 2a in 65% crude purity via the mesylate intermediate 27a and
88% crude purity via the iodide 27b. We utilized this procedure (through the iodide) to create 32 new
compounds and demonstrate the ability to introduce three points of variability (with basic functionality
in R3) in structure 2. The results with purified yields are shown in Table 2.

Molecules 2010, 15
4965
Table 2. 32 compounds from 4 alkylating agents, 4 carboxylic acids and 2 amines.
O
R1
N
O
R1
N
Cl
H
H
N
N
OMe
N
N
R2
N
R2
N
H
H
O
O
3a-3p
3q-3af
F
F
OCH3
F
OCH3
F
R1
X
(CH2)5CH3
(CH2)5CH3
I
I
Cl
Cl
Br
Cl
Cl
Br
O
R2 OH
O
3a (46%)
3e (51%)
3i (70%)
3m (67%)
3q (48%)
3u (43%)
3y (41%)
3ac (45%)
3b (49%)
3f (37%)
3j (39%)
3n (36%)
3c (19%)
3g (53%)
3k (49%)
3o (54%)
3d (76%)
3r (41%)
3v (26%)
3z (19%)
3ad (27%)
3s (33%)
3w (32%)
3aa (35%)
3ae (33%)
3t (41%)
OH
O
OH
3h (62%)
3l (76%)
3p (78%)
3x (44%)
3ab (54%)
3af (54%)
O
OH
O
N
OH
Conclusions
This procedure provides ready access to the fundamental peptide scaffold 1 with multiple
substitutions at positions R1, R2, and R3. The average overall purified yield to combinatorially prepare
the 32 compounds 3a-3af using this 11-step synthetic sequence was 46%. The R3 site can contain basic
residues. Alternatively, based on ample precedent [12], the key iodide intermediate 27b could provide
access to many other interesting and valuable derivatives of 2 via simple nucleophilic displacement
reactions.
Experimental
General
Organic solvents were of reagent grade and used directly without purification. Chloroform-d1, 1-
chloro-3-iodopropane, 1-(3-chlorophenyl)piperazine, cyclohexanecarboxylic acid, DIPCDI (N,N’-di-
isopropylcarbodiimide), anhydrous DMF (N,N-dimethylformamide), 1-iodohexane and methane-
sulfonyl chloride were purchased from Acros Organics. TFA (trifluoroacetic acid) and hydrochloric
acid were obtained from Fisher Scientific. BTPP [tert-butylimino-tri(pyrrolidino)phosphorane] was
purchased from Fluka. 3-Amino-1-propanol, benzoic acid, benzoyl peroxide, NBS (N-bromo-
succinimide), tert-butylchlorodiphenylsilane, 1-chloro-4-iodobutane, 1-chloro-5-iodopentane, cyclo-
propanecarboxylic acid, 4-cyanobenzoic acid, 3,4-dichlorobenzaldehyde, 1-(2,3-dichlorophenyl)-
piperazine hydrochloride, α,α’-dichloro-o-xylene, DAST [(diethylamino)sulfur trifluoride], DIEA
(N,N-diisopropylethylamine), HOBt (1-hydroxybenzotriazole hydrate), imidazole, 1-iodooctane,

Molecules 2010, 15
4966
methanol-d4, 1-(2-methoxyphenyl)piperazine, anhydrous NMP (1-methyl-2-pyrrolidinone), piperidine,
anhydrous pyridine, quinaldic acid, 1,2,3,4-tetrahydroisoquinoline, TBAF (tetrabutylammonium
fluoride), triethylamine, anhydrous TMOF (trimethyl orthoformate), and triphenylphosphine were
obtained from Aldrich Chemical Co. Iodine was obtained from J. T. Baker. 4-Methylbenzhydrylamine
hydrochloride resin (PL-MBHA·HCl, 1.6 mmol/g, 75–150 μm) was purchased from Polymer
Laboratories. 4-(4-Formyl-3,5-dimethoxyphenoxy)butyric acid (BAL linker), Fmoc-Gly-OH (N-Fmoc-
glycine), and HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate)
were purchased from NovaBiochem. Diethyl [(4-α-bromomethyl)phenyldifluoromethyl]phosphonate
[6] and O-tert-butyldiphenylsilyl-3-aminopropanol hydrochloride [13] were prepared according to
literature procedures. Solution and solid-phase organic transformations and resin washes were carried
out at ambient temperature, unless indicated otherwise. Ratios in all solvent and reagent mixtures
prepared are volume to volume unless otherwise noted.
Manual solid-phase organic syntheses were carried out in two types of reaction vessels. Peptide
synthesis reaction vessels (50 mL) with coarse porosity fritted glass support and supplied with a GL
thread and a Teflon-lined PBT screw cap (ChemGlass, CG-1860-03) were used for large scale (up to
3.7 mmol) reactions. Small scale reactions (typically 50 μmol) were performed in 3.5 mL fritted glass
reaction vessels (Chemglass, IUP-0305-270H) equipped with polypropylene screw caps (Chemglass,
CV-3730-G013) with Teflon-faced silicon septa (Chemglass, CV-4080-0013) on the Bill-Board set,
which was designed by one of us (WLS) as inexpensive equipment [2,14] to simplify and expedite
multiple, manual solid-phase syntheses. For agitation purpose, the large scale reactions in the peptide
synthesizers were placed on an orbital shaker Roto Mix (Type 50800 by Thermolyne) while
appropriate motor rotators were used as rotation apparatus for small scale reactions.
Depending on the number of reactions to be performed, the starting resin was distributed either by
weight or as aliquots from an isopycnic suspension [2]. In the case of distribution by volume from an
isopycnic suspension, the Bill-Boards were placed in their drain trays, and from a neutral buoyancy
suspension in CH2Cl2–NMP, 50 μmols of the starting resin (with a known loading) was typically
distributed, via repeated aliquots (1 mL), to each of the reaction vessels in a given Bill-Board (6-pack
or 24-pack). During the distribution of the resin, the isopycnic solvent was allowed to drain through
the frit in the reaction vessels. When distribution was complete, residual solvent was removed with an
“air-push” from a disposable plastic pipet (Fisher, 13-711-23) fitted with a pierced septum (Aldrich, Z
12743-4). The resin was then washed with an appropriate solvent (this solvent wash was also carried
out when the resin was weighed into the reaction vessels). The bottom of each reaction vessel was then
capped, and a new calibrated pipet (Fisher, 13-711-24) was used for adding each reagent in the
following step. The tops of all reaction vessels were capped and the Bill-Board was placed on an
appropriate rotation apparatus. Following the reaction the reagents and solvents were drained and the
resin product was then washed with the indicated solvents. Resin-bound intermediates were air-dried
after the final CH2Cl2 washes, unless re-weighing was necessary, in which case overnight drying was
carried out under high vacuum (≤ 0.2 mm Hg) or under low vacuum (house vacuum) for 24–36 h in a
vacuum desiccator. During resin washing with solvents for large scale reactions, at least 3 min of
solvent contact with the resin in the reaction vessels (bottom closed) was performed, then the resin was
drained, followed by an air-push. For washing of small scale reactions, at least 30 sec was normally
used after addition of solvents to the reaction vessels (with bottom end open for draining) followed by

Molecules 2010, 15
4967
an air-push. Solid-phase reactions at elevated temperatures (50 °C, 60 °C and/or 80 °C) were carried
out in an Isotemp® Oven Model 280A (Fisher Scientific) with the reaction vessels capped to finger
tightness.
Analytical thin layer chromatography (TLC) was performed with EM Science silica gel 60 F254,
0.25 mm pre-coated glass plates (EMD Chemical Inc., 5715-7). TLC plates were visualized using
UV254. Column chromatography was performed on HyperSep SI® 3 mL cartridges (60108-315) pre-
loaded with 500 mg of silica gel 60 (irregular particles 40–63 μm) from Thermo Electron Corporation.
The yields of the final compounds, after chromatographic purification, were calculated on the basis of
the initial loading of the starting resins and are the overall yields for all reaction steps starting from
1
these resins. H-NMR (500 MHz) and 13C -NMR (125 MHz) spectra were recorded on a Bruker
Avance III 500 spectrometer. Chemical shifts are reported in parts per million (ppm) and are
1
13
referenced to the centerline of chloroform-d1 (δ 7.26 ppm H-NMR, 77.0 ppm C-NMR) using TMS
(0.00 ppm), or chloroform-d1 mixed with methanol-d4 (2–10%). Coupling constants are given in
Hertz (Hz).
Electrospray ionization mass spectrometry was conducted using a PESciex API III triple stage
quadrupole mass spectrometer operated in either positive-ion or negative-ion detection mode. LC/MS
analyses were conducted using an Agilent system, consisting of a 1100 series HPLC connected to a
diode array detector and a 1946D mass spectrometer configured for positive-ion/negative-ion electro-
spray ionization. The LC/MS samples were analyzed as solutions in CH3CN, prepared at 0.08–0.12
mg/mL concentration. The LC/MS derived composition of mixtures was determined based on UV
integration at 210 nm. The LC/MS chromatography was carried out on an Agilent Zorbax SB–C8
column (PN835975-906; 4.6 × 50 mm, 3.5 μm) with linear gradients of 0.1% TFA in CH3CN and
0.1% aqueous TFA and were run at 1.0 mL/min flow rate from 20:80 to 90:10 for 25 min. The
composition of reaction mixtures was determined based on the integration of NMR spectra as well as
LC/MS results. High-resolution mass spectrometry was obtained on a MAT 95XP (Thermo Electron
Corp.) with chemical ionization (CI), electron impact (EI), or fast-atom bombardment (FAB) mode.
General procedures for manual solid-phase organic syntheses
Preparation of MBHA-BAL Resin 4: PL-MBHA·HCl resin (1.03 g, 1.65 mmol, 1.60 mmol/g) loaded in
a 50 mL peptide synthesis reaction vessel was sequentially washed with DMF (3 × 17 mL), CH2Cl2
(2 × 17 mL), 10% DIEA/CH2Cl2 (5 × 17 mL) and CH2Cl2 (2 × 17 mL). A solution of 4-(4-formyl-3,5-
dimethoxyphenoxy)butyric acid (1.77 g, 6.60 mmol, 4 equiv), HBTU (2.50 g, 6.60 mmol, 4 equiv)
and DIEA (2.30 mL, 13.2 mmol, 8 equiv) in anhydrous DMF (23 mL) prepared immediately prior to
the reaction was then added to the washed resin. The reaction mixture was agitated on an orbital
shaker for 18 h. The completion of the reaction was confirmed by a negative chloranil test [15]. The
resultant orange yellow MBHA-BAL resin 4 was washed with DMF (3 × 17 mL) and CH2Cl2
(4 × 17 mL), and dried under low vacuum for 24 h.
Preparation of the Secondary Amine-Bound Resin 21 by Reductive Amination: The dried MBHA-BAL
resin 4 (1.51 g, 1.65 mmol) was swelled in CH2Cl2 (17 mL) for 1 h, followed by DMF washes
(3 × 17 mL). O-tert-Butyldiphenylsilyl-3-aminopropanol hydrochloride [13] (8.66 g, 24.75 mmol,

Molecules 2010, 15
4968
15 equiv) was added as a solid followed by addition of DMF–TMOF (1:2, 28 mL) to the resin. The
resulting reaction mixture was heated to 60 °C for 24 h. The resin-bound Schiff base product was
washed with DMF (4 × 17 mL), THF (5 × 17 mL), MeOH (2 × 17 mL), CH2Cl2 (2 × 17 mL), and
MeOH (3 × 17 mL). After the resulting imine resin was swelled in CH2Cl2 (17 mL) for 30 min
followed by THF (17 mL) wash, it was treated with a solution of NaBH3CN (1.04 g, 16.5 mmol, 10
equiv) in 5% HOAc in THF–MeOH (1:1, 28 mL). The reaction mixture was agitated on an orbital
shaker for 18 h. The resin was drained and washed with THF–MeOH (1:1, 3 × 17 mL), MeOH
(2 × 17 mL), THF (3 × 17 mL) and CH2Cl2 (3 × 17 mL). The amine resin product 21 was air-dried and
was then used directly for subsequent coupling reactions.
Coupling of the Amine Resin 21 with N-Fmoc-Glycine using HBTU to Prepare Resin-Bound 22: The
amine resin 21 (1.65 mmol) was swelled in CH2Cl2 (17 mL) for 30 min, and then it was washed with
CH2Cl2–DMF (85:15, 17 mL). Fmoc-Gly-OH (2.45 g, 8.25 mmol, 5 equiv), HBTU (3.13 g,
8.25 mmol, 5 equiv), CH2Cl2–DMF (85:15, 39 mL) and DIEA (2.87 mL, 16.5 mmol, 10 equiv) were
then added to the reaction vessel. The reaction mixture was agitated on an orbital shaker for 42 h. The
completion of the reaction was indicated by a negative chloranil test [15]. The resulting Fmoc-Gly-
BAL resin product 22 was then washed with DMF (3 × 17 mL), THF–MeOH (1:1, 3 × 17 mL), THF
(3 × 17 mL), and CH2Cl2 (3 × 17 mL). The washed resin 22 was dried under low vacuum for 24–36 h.
Preparation of the 3,4-Dichlorobenzaldehyde Imine of Glycine on BAL Resin 23: The resin 22
(1.65 mmol) was swelled in CH2Cl2 (17 mL) for 30 min, and washed with DMF (5 × 17 mL), then it
was treated with 20% piperidine/DMF (23 mL, 20 min) and subsequently washed with DMF
(6 × 17 mL). The resin was swelled in CH2Cl2 (17 mL) for 30 min and washed with NMP (4 × 17 mL).
A solution of 3,4-dichlorobenzaldehyde (1.25 M, 19.8 mL, 24.75 mmol, 15 equiv) in NMP–TMOF
(1:2) was then added to the reaction vessel and the reaction mixture was rotated for 24 h. The resulting
resin-bound Schiff base product 23 was sequentially washed with NMP (4 × 17 mL), THF
(3 × 17 mL), CH2Cl2 (3 × 17 mL) and dried under low vacuum for 24 h.
Alkylation of the Aldimine of Glycine on BAL Resin 23 with Alkyl Halides, Subsequent Imine
Hydrolysis, and Acylation with Carboxylic Acids: After resin-bound Schiff base 23 (50 μmol) was
pre-swelled in CH2Cl2 for 1 h, it was washed with NMP (4 × 1 mL). To the resin was then added a
solution of R1X in NMP (2.0 M, 0.25 mL, 0.5 mmol, 10 equiv), followed by addition of BTPP solution
in NMP (2.0 M, 0.25 mL, 0.5 mmol, 10 equiv). Alkylation was allowed to proceed at ambient
temperature for 24 h with rotation. The alkylated resin product was filtered and washed with NMP
(4 × 1 mL), CH2Cl2 (4 × 1 mL) and THF (3 × 1 mL). The resin was then treated with 1N HCl–THF
(1:2, 1 mL) for 20 min. The resulting resin was filtered and washed with THF (3 × 1 mL), 10%
DIEA/CH2Cl2 (5 × 1 mL), CH2Cl2 (2 × 1 mL). After the resin was swelled in CH2Cl2 (1 mL) for 1 h,
and washed with DMF (3 × 1 mL), to the resin was added a solution of carboxylic acid R2COOH and
HOBt in DMF (0.38 M, 0.66 mL, 0.25 mmol, 5 equiv), which was pre-mixed (6 - 10 min before
addition) with DIPCDI (neat, 32 mg, 0.25 mmol, 5 equiv). The reaction mixture was allowed to rotate
for 18 h. The completion of the reaction was confirmed by a negative chloranil test [15], and the

Molecules 2010, 15
4969
filtered resin product 25 was washed with DMF (4 × 1 mL), THF (3 × 1 mL), CH2Cl2 (3 × 1 mL), and
dried in air.
Model Studies for the Synthesis of 2a–2d via Deprotection of Silyl Ether 25 with TBAF, Subsequent
Mesylation of Alcohol 26 using Mesyl Chloride in Pyridine, and N-Alkylation with
Tetrahydroisoquinoline: The acylated resin product 25 (50 μmol) was washed with THF (3 × 1 mL),
and swelled in THF for 1 h. TBAF (1 M in THF, 1.0 mL, 1.0 mmol, 20 equiv) was added to the
drained resin, and the reaction mixture was allowed to rotate for 18 h. The drained resin was then
washed with THF (5 × 1 mL) and CH2Cl2 (3 × 1 mL). After the alcohol resin 26 was swelled in
CH2Cl2 for 1 h, a suspension of anhydrous pyridine with MsCl (1 M, 1.0 mL, 0.5 mmol, 20 equiv) was
added to the resin, and the resulting mixture was rotated for 1 h. The drained resin product 27a was
washed with DMF (3 × 1 mL), H2O (1 × 1 mL), DMF (2 × 1 mL) and CH2Cl2 (5 × 1 mL). After the
air-dried resin was swelled in CH2Cl2 for 30 min, to the resin was added a solution of
tetrahydroisoquinoline in DMSO (1 M, 0.75 mL, 0.75 mmol, 15 equiv), and the reaction mixture was
heated to 80 °C for 5 h. The resulting resin product was drained, washed with DMF (2 × 1 mL), H2O
(2 × 1 mL), DMF (3 × 1 mL), CH2Cl2 (4 × 1 mL), and air-dried. The resin product was then cleaved
with 50% TFA/CH2Cl2 (1 mL) over 1.5 h, and the filtrate of the reaction mixture was collected and
combined with washes of CH2Cl2 (2 × 1 mL) of the resin. A 100 μL sample of the combined solution
was analyzed for crude purity by LC/MS. The cleavage solution was evaporated with a stream of
nitrogen in a contained system with trapping of the evaporated TFA in 2N NaOH. The crude residue
was re-dissolved in CH2Cl2, or CH2Cl2 with MeOH, if needed (total solution volume ≤0.5 mL), and
purified using a pre-loaded silica gel cartridge with CH2Cl2–MeOH (95:5 or 93:7) to elute the purified
product. Following solvent removal under N2 flow, the purified product 2a–2d was normally obtained
as an amorphous white solid or light yellow oil.
α-[(4-Cyanobenzoyl)amino]-N-[(3,4-dihydroisoquinolin-2(1H)-yl)propyl]-benzenepropanamide (2a):
Product 2a was obtained from resin 23, benzyl bromide, 4-cyanobenzoic acid, and
tetrahydroisoquinoline as an amorphous white solid (6 mg, 26% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 65%, tR
1
= 7.3 min; H-NMR (CD3OD/CDCl3): δ 1.67–1.78 (m, 2H), 2.49–2.61 (m, 3H), 2.74–2.86 (m, 2H),
2.88–2.93 (m, 1H), 2.96 (dd, J = 8.0 Hz, J = 13.5 Hz, 1H), 3.03 (dd, J = 6.0 Hz, J = 13.5 Hz, 1H),
3.24–3.32 (m, 1H), 3.37–3.44 (m, 1H), 3.51–3.61 (m, 2H), 4.53 (dd, J = 7.7 Hz, J = 13.8 Hz, 1H),
6.95–7.01 (m, 2H), 7.02–7.06 (m, 2H), 7.12–7.18 (m, 3H), 7.19–7.23 (m, 3H), 7.32–7.36 (m, 1H), 7.69
(d, J = 8.5 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H). 13C-NMR (CD3OD/CDCl3): δ 23.7, 24.2, 35.8, 37.8, 49.1,
51.9, 52.5, 55.8, 115.2, 117.9, 126.1, 126.8, 126.9, 127.6, 128.1, 128.6, 128.7, 128.9, 129.2, 130.1,
132.2, 136.6, 137.3, 166.2, 172.6. HRMS calcd. for (M + H)+: C29H31N4O2 467.2447, found 467.2431.
2-[(4-Cyanobenzoyl)amino]-N-[(3,4-dihydroisoquinolin-2(1H)-yl)propyl]-4-pentenamide (2b): This
product was obtained from resin 23, allyl bromide, 4-cyanobenzoic acid, and tetrahydroisoquinoline as
a light yellow oil (4 mg, 19% isolated yield) following chromatographic purification over silica gel
1
with CH2Cl2–MeOH (92:8). Initial LC/MS purity 60%, tR = 5.4 min; H-NMR (CD3OD/CDCl3): δ
1.97–2.04 (m, 2H), 2.49–2.58 (m, 1H), 2.60–2.68 (m, 1H), 3.06–3.11 (m, 3H), 3.24–3.31 (m, 1H),

Molecules 2010, 15
4970
3.32–3.38 (m, 1H), 3.40–3.48 (m, 2H), 4.03–4.19 (m, 2H), 4.29 (s, 1H), 4.61 (dd, J = 6.0 Hz,
J = 7.7 Hz, 1H), 5.05–5.21 (m, 2H), 5.65–5.82 (m, 1H), 7.06 (d, J = 7.5 Hz, 1H), 7.08–7.14 (m, 1H),
7.18 (d, J = 7.1 Hz, 1H), 7.21–7.28 (m, 3H), 7.70 (d, J = 8.3 Hz, 2H), 7.97 (d, J = 8.5 Hz, 2H). 13C-
NMR (CD3OD/CDCl3): δ 24.2, 25.3, 36.4, 36.7, 41.5, 44.4, 53.5, 53.8, 115.3, 118.0, 118.9, 126.6,
126.7, 127.2, 127.3, 128.1, 128.9, 129.0, 132.3, 132.8, 137.4, 166.1, 172.3. HRMS calcd. for (M + H)+:
C25H29N4O2 417.2212, found 417.2200.
2-[(4-Cyanobenzoyl)amino]-N-[(3,4-dihydroisoquinolin-2(1H)-yl)propyl]decanamide (2c): Product 2c
was obtained from resin 23, 1-iodooctane, 4-cyanobenzoic acid, and tetrahydroisoquinoline as a light
yellow oil (7 mg, 29% isolated yield) following chromatographic purification over silica gel with
CH2Cl2–MeOH (95:5). Initial LC/MS purity 65%, tR = 11.8 min; 1H-NMR (CD3OD/CDCl3): δ 0.86 (t,
J = 7.0 Hz, 3H), 1.17–1.48 (m, 12H), 1.71–1.95 (m, 2H), 1.99–21.6 (m, 2H), 2.99–3.52 (m, 7H),
3.55–3.79 (m, 1H), 3.92–4.25 (m, 1H), 4.30–4.69 (m, 2H), 7.03–7.15 (m, 1H), 7.20 (d, J = 7.1 Hz,
1H), 7.24–7.34 (m, 3H), 7.71 (d, J = 8.5 Hz, 2H), 8.00 (d, J = 8.7 Hz, 2H). 13C-NMR (CD3OD/CDCl3):
δ 14.0, 22.6, 23.8, 24.3, 25.9, 29.1, 29.2, 29.3, 31.7, 32.0, 35.7, 49.3, 52.2, 52.6, 55.0, 115.2, 118.0,
126.1, 126.8, 127.6, 128.2, 128.7, 128.9, 130.1, 132.2, 137.4, 166.5, 171.1. HRMS calcd. for (M + H)+:
C30H41N4O2 489.3151, found 489.3138.
α-[(4-Cyanobenzoyl)amino]-4-[(ethoxyhydroxyphosphinyl)difluoromethyl]-N-[(3,4-dihydroisoquinolin
-2(1H)-yl)propyl]benzenepropanamide (2d): Product 2d was obtained from resin 23, diethyl [(4-α-
bromomethyl)phenyldifluoromethyl]-phosphonate, 4-cyanobenzoic acid, and tetrahydroisoquinoline as
a light yellow oil (6 mg, 19% isolated yield) following chromatographic purification over silica gel
1
with CH2Cl2–MeOH (92:8). Initial LC/MS purity 47%, tR = 5.9 min; H-NMR (CD3OD/CDCl3): δ
1.05–1.19 (m, 3H), 1.30–1.41 (m, 2H), 2.57–2.80 (m, 3H), 3.03–3.43 (m, 10H), 4.04–4.16 (1H), 4.25
(s, 1H), 4.70–4.83 (m, 1H), 7.08–7.36 (m, 8H), 7.56 (d, J = 7.3 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 8.01
13
(d, J = 8.2 Hz, 2H). C-NMR (125 MHz, CD3OD/CDCl3): δ 16.3, 22.9, 24.7, 36.1, 38.9, 41.6, 52.6,
52.8, 55.5, 62.6, 115.1, 117.9, 126.5, 126.7, 126.9, 127.1, 127.7, 128.0, 128.2, 128.5, 128.7, 128.9,
130.5, 132.2, 137.7, 165.6, 170.8. HRMS calcd. for (M + H)+: C32H37F2N4O5P 625.2313, found
625.2326.
Direct Comparison of Activation of Alcohol Resin 26 via Mesylation (to 27a) with that via Iodination
(to 27b) using Optimal N-Alkylation and Cleavage Conditions: The mesylation of the alcohol resin 26
was the same as described above. Iodination of the resin 26 was performed as follows. After the free
alcohol resin 26 was swelled in CH2Cl2 for 1 h and washed with DMF (3 × 1 mL), a pre-mixed
solution of iodine (63 mg, 0.25 mmol, 5 equiv), PPh3 (66 mg, 0.25 mmol, 5 equiv), and imidazole
(17 mg, 0.25 mmol, 5 equiv) in DMF (1.0 mL) was added. After 18 h, the filtered resin was washed
with DMF (3 × 1 mL), MeOH (3 × 1 mL), DMF (2 × 1 mL), and CH2Cl2 (3 × 1 mL). After mesylated
resin 27a and iodinated resin 27b were swelled in CH2Cl2 for 40 min, to each resin was added a
solution of tetrahydroisoquinoline in DMSO (1 M, 0.75 mL, 0.75 mmol, 15 equiv). The reaction was
heated to 80 °C over 3 h for mesylated resin or 50 °C over 6 h for iodinated resin. The resulting resin
products were drained, sequentially washed with DMF (2 × 1 mL), MeOH (2 × 1 mL), DMF
(3 × 1 mL), CH2Cl2 (4 × 1 mL), and cleaved with 90% TFA/CH2Cl2 (1 mL) over 1.5 h. The filtrate of

Molecules 2010, 15
4971
the reaction mixture was collected and combined with washes of 50% TFA/CH2Cl2 (1 × 1 mL) and
CH2Cl2 (1 × 1 mL) of the resin. A 100 μL sample of the combined solution was analyzed for crude
purity by LC/MS. The crude purity for the product 2 was found to be 65% for the product through the
mesylation and 88% for the product through the iodination process.
Synthesis of 32 New Resin Products 25 (Targeting Piperazine Derivatives 3) from the Same Aldimine
of Glycine on BAL Resin 23 through Alkylation, Hydrolysis, and Acylation: Resin-bound Schiff base
23 (1.65 mmol) pre-swelled in CH2Cl2 for 1 h was evenly distributed to 33 of the reaction vessels in
two separate 24-pack BillBoards via an isopycnic solution in CH2Cl2–NMP (9:5, v/v). 32 of the
reaction vessels were arranged as two 4 × 4 grids on the BillBoards, and the 33rd reaction vessel was
put at position on A5 on one of the BillBoards for the quality control experiment for the resin 23. After
the drained resin (50 μmol) was washed with NMP (4 × 1 mL), to the four reaction vessels down the
first column positions (i.e. A1, B1, C1 and D1) on both BillBoards were added 1-iodohexane (2.0 M,
0.25 mL, 0.50 mmol, 10 equiv). To the four reaction vessels down the 2nd column positions on both
BillBoards were added 4-methoxybenzyl chloride (2.0 M, 0.25 mL, 0.50 mmol, 10 equiv). To the four
reaction vessels down the 3rd column positions on both BillBoards were added 3-fluorobenzyl chloride
(2.0 M, 0.25 mL, 0.50 mmol, 10 equiv). To the four reaction vessels down the 4th column positions on
both BillBoards were added 4-fluorobenzyl bromide (2.0 M, 0.25 mL, 0.50 mmol, 10 equiv). To the
control reaction vessel was added a solution of BnBr in NMP (2.0 M, 0.25 mL, 0.50 mmol, 10 equiv)
for quality control of the starting resin 23.
Then a solution of BTPP in NMP (2.0 M, 0.25 mL, 0.50 mmol, 10 equiv) was added to each of the
33 reaction vessels. Alkylation was allowed to proceed at ambient temperature for 24 h with rotation.
The alkylated resin product was filtered and washed with NMP (4 × 1 mL), CH2Cl2 (4 × 1 mL) and
THF (3 × 1 mL). The resin was then treated with 1N HCl–THF (1:2, 1 mL) for 20 min. The resulting
resin was filtered and washed with THF (3 × 1 mL), 10% DIEA/CH2Cl2 (5 × 1 mL), CH2Cl2 (2 × 1 mL).
After the resin was swelled in CH2Cl2 (1 mL) for 1 h, and washed with DMF (3 × 1 mL), to the resins
across row A positions (i.e. A1, A2, A3, A4) on both BillBoards were added a solution of
cyclopropanecarboxylic acid and HOBt in DMF (0.38 M, 0.66 mL, 0.25 mmol, 5 equiv) which was
pre-mixed (6 - 10 min before addition) with DIPCDI (32 mg, 0.25 mmol, 5 equiv). To the resins across
row B positions on both BillBoards were added a solution of cyclohexanecarboxylic acid and HOBt in
DMF (0.38 M, 0.66 mL, 0.25 mmol, 5 equiv) which was pre-mixed (6 - 10 min before addition) with
DIPCDI (32 mg, 0.25 mmol, 5 equiv). To the resins across row C positions on both BillBoards were
added a solution of benzoic acid and HOBt in DMF (0.38 M, 0.66 mL, 0.25 mmol, 5 equiv) which was
pre-mixed (6 - 10 min before addition) with DIPCDI (32 mg, 0.25 mmol, 5 equiv). To the resins across
row D positions on both BillBoards were added a solution of quinaldic acid and HOBt in DMF
(0.38 M, 0.66 mL, 0.25 mmol, 5 equiv) which was pre-mixed (6 min before addition) with DIPCDI (32
mg, 0.25 mmol, 5 equiv; and it was observed that the colorless clear solution turned purple 2 min after
DIPCDI was added). To the quality control reaction vial was added a solution of benzoic acid and
HOBt in DMF (0.38 M, 0.66 mL, 0.25 mmol, 5 equiv) which was pre-mixed (6 - 10 min before
addition) with DIPCDI (neat, 32 mg, 0.25 mmol, 5 equiv). The reaction mixture was rotated for 18 h.
The completion of the reaction was confirmed by a negative chloranil test [15], and the filtered resin
product 25 was washed with DMF (4 × 1 mL), THF (3 × 1 mL), CH2Cl2 (3 × 1 mL), and dried in air.

Molecules 2010, 15
4972
Deprotection of the Silyl Ether on Resin 25 with TBAF and Subsequent Iodination using
Triphenylphosphine, Iodine and Imidazole to Form Resin-Bound 27b: The resin product 25 was
swelled in CH2Cl2 for 40 min, and the drained resin was washed with THF (3 × 1 mL). To the resin
was added TBAF/THF (1 M, 1.0 mL, 1.0 mmol, 20 equiv), and the reaction was allowed to proceed
for 18 h. The drained resin was washed with THF (3 × 1 mL), and CH2Cl2 (3 × 1 mL), and air dried.
After this alcohol resin was swelled in CH2Cl2 for 1 h and washed with DMF (3 × 1 mL), a pre-mixed
solution of iodine (63 mg, 0.25 mmol, 5 equiv), PPh3 (66 mg, 0.25 mmol, 5 equiv), and imidazole
(17 mg, 0.25 mmol, 5 equiv) in DMF (1.0 mL) was added. After 18 h, the filtered resin was washed
with DMF (3 × 1 mL), MeOH (3 × 1 mL), DMF (2 × 1 mL), and CH2Cl2 (3 × 1 mL).
Displacement of Iodo-Resin 27b with Amines and Subsequent Cleavage to Target Molecules 3: The
air-dried resin 27b was swelled in CH2Cl2 for 40 min, and to the first 16 reaction vessels on one
BillBoard were added a solution of 2-methoxyphenyl piperazine in anhydrous DMSO (1 M, 0.75 mL,
0.75 mmol, 15 equiv), while to the other 16 reaction vessels on the other BillBoard were added a
solution of 3-chlorophenyl piperazine in anhydrous DMSO (1 M, 0.75 mL, 0.75 mmol, 15 equiv), and
to the resin for quality control was added a tetrahydroisoquinoline solution in DMSO (1M, 0.75 mL,
◦
0.75 mmol, 15 equiv). All reaction vessels were heated to 50 C for 6 h with occasional agitation. The
resulting resin product was drained, sequentially washed with DMF (2 × 1 mL), MeOH (2 × 1 mL),
DMF (3 × 1 mL), CH2Cl2 (4 × 1 mL), and cleaved with 90% TFA/CH2Cl2 (1 mL) over 1.5 h, affording
the target compound 3.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-octanamide (3a):
Product 3a was obtained from resin 23, 1-iodohexane, cyclopropanecarboxylic acid, and 2-methoxy-
phenylpiperazine as an amorphous light yellow solid (10.5 mg, 46% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (92:8). Initial LC/MS purity 81%, tR
1
= 8.2 min; H-NMR (CDCl3): δ 0.71–0.78 (m, 2H), 0.86 (t, J = 6.9 Hz, 3H), 0.89–0.96 (m, 2H),
1.19–1.38 (m, 10H), 1.42–1.51 (m, 1H), 1.57–1.69 (m, 1H), 1.79–1.90 (m, 3H), 2.74–2.83 (m, 2H),
2.89–3.02 (m, 3H), 3.18–3.28 (m, 3H), 3.33–3.43 (m, 2H), 3.87 (s, 3H), 4.36 (dd, J = 7.8 Hz,
J = 13.7 Hz, 1H), 6.60 (d, J = 7.1 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 6.91–6.97 (m, 2H), 7.01–7.09 (m,
13
2H), 7.52–7.65 (m, 1H). C-NMR (CDCl3): δ 7.3, 7.4, 14.0, 14.6, 22.6, 24.4, 25.7, 29.0, 31.7, 32.8,
37.7, 49.3, 53.0, 53.8, 55.4, 55.9, 111.3, 118.6, 121.2, 123.8, 140.1, 152.2, 172.7, 173.8. HRMS calcd.
for (M + H)+: C26H42N4O3 459.3335, found 459.3313.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-methoxy-
phenyl)propanamide (3b): Product 3b was obtained from resin 23, 4-methoxybenzyl chloride,
cyclopropanecarboxylic acid, and 2-methoxyphenylpiperazine as light yellow oil (12.2 mg, 49%
isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
1
Initial LC/MS purity 78%, tR = 6.1 min; H-NMR (CDCl3): δ 0.67–0.77 (m, 2H), 0.84–0.95 (m, 2H),
1.43–1.53 (m, 1H), 1.78–1.90 (m, 2H), 1.97–2.07 (m, 1H), 2.37 (t, J = 8.1 Hz, 1H), 2.68–2.79 (m, 2H),
2.84 (s, 1H), 2.98–3.05 (m, 2H), 3.20–3.29 (m, 4H), 3.33–3.42 (m, 2H), 3.76 (s, 3H), 3.86 (s, 3H),
4.50–4.79 (m, 1H), 6.81 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 6.91–6.95 (m, 2H), 7.03–7.08

Molecules 2010, 15
4973
(m, 1H), 7.14 (d, J = 8.5 Hz, 2H), 7.46 (brs, 1H). 13C-NMR (CDCl3): δ 7.4, 7.5, 14.6, 17.7, 23.9, 29.6,
30.7, 37.6, 44.0, 48.7, 49.5, 52.8, 55.2, 55.5, 111.3, 113.9, 118.7, 121.2, 123.9, 128.8, 130.5, 139.7,
152.2, 158.5, 171.9, 174.0. HRMS calcd. for (M + H)+: C28H39N4O4 495.2907, found 495.2914.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(3-fluoro-
phenyl)propanamide (3c): Product 3c was obtained from resin 23, 3-fluorobenzyl chloride,
cyclopropanecarboxylic acid, and 2-methoxyphenylpiperazine as light yellow oil (4.6 mg, 19%
isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
1
Initial LC/MS purity 65%, tR = 6.5 min; H-NMR (CDCl3): δ 0.66–0.82 (m, 2H), 0.85–0.99 (m, 2H),
1.32–1.49 (m, 1H), 1.61–1.81 (m, 2H), 2.48–2.64 (m, 2H), 2.65–2.87 (m, 3H), 3.03–3.22 (m, 5H),
3.24–3.47 (m, 3H), 3.87 (s, 3H), 4.49–4.69 (m, 1H), 6.53 (brs, 1H), 6.87 (d, J = 8.1 Hz, 1H), 6.90–6.97
13
(m, 4H), 6.98–7.06 (m, 2H), 7.21–7.25 (m, 1H), 7.34 (brs, 1H). C-NMR (CDCl3): δ 7.4, 7.5, 14.7,
24.4, 31.8, 38.7, 50.1, 53.2, 53.3, 54.9, 55.4, 77.6, 111.2 113.7, 116.4, 118.4, 121.1, 123.4, 125.1,
129.9, 139.4, 140.6, 152.2, 161.8, 163.8, 170.7, 173.5. HRMS calcd. for (M + H)+: C27H36FN4O3
483.2771, found 483.2766.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-fluoro-
phenyl)propanamide (3d): Product 3d was obtained from resin 23, 4-fluorobenzyl bromide,
cyclopropanecarboxylic acid, and 2-methoxyphenylpiperazine as light yellow oil (18.3 mg, 76%
isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
1
Initial LC/MS purity 83%, tR = 6.4 min; H-NMR (CDCl3): δ 0.66–0.77 (m, 2H), 0.78–0.94 (m, 2H),
1.42–1.55 (m, 1H), 1.81–1.99 (m, 2H), 2.79–2.93 (m, 2H), 3.02 (dd, J = 7.4 Hz, J = 13.8 Hz, 2H), 3.09
(dd, J = 6.5 Hz, J = 13.8 Hz, 2H), 3.22–3.43 (m, 6H), 3.87 (s, 3H), 4.68 (dd, J = 7.3 Hz, J = 14.6 Hz,
1H), 6.89 (d, J = 8.4 Hz, 1H), 6.91–7.02 (m, 5H), 7.04–7.09 (m, 1H), 7.16–7.24 (m, 2H), 7.62 (brs,
13
1H). C-NMR (CDCl3): δ 7.4, 7.5, 14.7, 23.8, 36.5, 37.5, 48.1, 52.6, 54.8, 55.0, 55.4, 111.4, 115.2
115.4, 118.7, 121.2, 124.3, 130.9, 132.6, 139.2, 152.2, 160.9, 162.8, 172.1, 174.2. HRMS calcd. for (M
+ H)+: C27H36FN4O3 483.2771, found 483.2755.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}octanamide (3e):
Product 3e was obtained from resin 23, 1-iodohexane, cyclohexanecarboxylic acid, and 2-methoxy-
phenylpiperazine as light yellow oil (12.8 mg, 51% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 81%, tR = 10.8 min; H-
NMR (CDCl3): δ 0.85 (t, J = 6.8 Hz, 3H), 1.20–1.30 (m, 11H), 1.36–1.48 (m, 2H), 1.58–1.68 (m, 2H),
1.73–1.88 (m, 7H), 1.97–2.07 (m, 0.5H), 2.08–2.21 (m, 1H), 2.38 (t, J = 8.1 Hz, 0.5H), 2.65–2.79 (m,
2H), 2.82–2.96 (m, 3H), 3.13–3.26 (m, 3H), 3.29–3.48 (m, 3H), 3.88 (s, 3H), 4.35 (dd, J = 7.6 Hz,
J = 13.9 Hz, 1H), 6.38 (brs, 1H), 6.87 (d, J = 8.1 Hz, 1H), 6.89–6.96 (m, 2H), 6.99–7.06 (m, 1H), 7.64
13
(brs, 1H). C-NMR (CDCl3): δ 14.0, 17.7, 22.5, 24.6, 25.6, 25.7, 29.0, 29.3, 29.8, 30.7, 31.6, 32.8,
38.2, 45.3, 49.7, 53.2, 55.4, 111.3, 118.5, 121.1, 123.5, 140.4, 152.2, 172.5, 176.5. HRMS calcd. for
(M + H)+: C29H49N4O3 501.3805, found 501.3811.

Molecules 2010, 15
4974
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3(4-methoxy-
phenyl)propanamide (3f): Product 3f was obtained from resin 23, 4-methoxybenzyl chloride, cyclo-
hexanecarboxylic acid, and 2-methoxyphenylpiperazine as light yellow oil (9.9 mg, 37% isolated
yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial
1
LC/MS purity 65%, tR = 8.7 min; H-NMR (CDCl3): δ 1.16–1.27 (m, 3H), 1.32–1.43 (m, 2H), 1.61–
1.69 (m, 3H), 1.72–1.83 (m, 4H), 1.97–2.04 (m, 1H), 2.05–2.13 (m, 1H), 2.38 (t, J = 8.1 Hz, 1H),
2.45–2.52 (m, 2H), 2.62–2.66 (m, 1H), 2.68–2.73 (m, 1H), 2.84 (s, 1H), 2.97 (d, J = 7.1 Hz, 2H), 3.06–
3.13 (m, 2H), 3.22–3.34 (m, 2H), 3.38 (t, J = 7.1 Hz, 1H), 3.76 (s, 3H), 3.86 (s, 3H), 4.50 (dd, J = 7.2
Hz, J = 14.6 Hz, 1H), 6.30 (d, J = 7.2 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 7.9 Hz, 1H), 6.94
(d, J = 4.2 Hz, 2H), 6.99–7.05 (m, 1H), 7.11 (d, J = 8.6 Hz, 2H), 7.19 (brs, 1H). 13C-NMR (CDCl3): δ
17.7, 25.6, 25.7, 29.3, 29.7, 30.7, 38.1, 45.2, 49.5, 53.2, 54.7, 55.2, 55.4, 56.6, 111.2, 114.1, 118.4,
121.1, 123.3, 128.8, 130.4, 140.7, 152.2, 158.5, 171.1, 175.9. HRMS calcd. for (M + H)+: C31H45N4O4
537.3441, found 537.3439.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(3-fluoro-
phenyl)propanamide (3g): Product 3g was obtained from resin 23, 3-fluorobenzyl chloride, cyclo-
hexanecarboxylic acid, and 2-methoxyphenylpiperazine as yellow oil (13.9 mg, 53% isolated yield)
following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS
1
purity 65%, tR = 9.1 min; H-NMR (CDCl3): δ 1.14–1.37 (m, 5H), 1.60–1.78 (m, 5H), 1.93–2.07 (m,
3H), 2.08–2.18 (m, 1H), 2.37 (t, J = 8.2 Hz, 1H), 2.84 (s, 1H), 2.94–3.05 (m, 3H), 3.16 (dd, J = 6.0 Hz,
J = 13.9 Hz, 2H), 3.27–3.34 (m, 3H), 3.35–3.44 (m, 3H), 3.87 (s, 3H), 4.66 (dd,
J = 7.9 Hz, J = 14.1 Hz, 1H), 6.60 (d, J = 7.8 Hz, 1H), 6.86–6.97 (m, 5H), 7.00 (d, J = 7.7 Hz, 1H),
7.05–7.11 (m, 1H), 7.21–7.25 (m, 1H), 7.60–7.70 (m, 1H). 13C-NMR (CDCl3): δ 17.7, 23.7, 25.7, 29.1,
29.7, 30.7, 37.7, 44.9, 47.7, 49.5, 52.5, 54.4, 55.5, 111.4, 113.7, 116.3, 118.9, 121.2, 124.5, 125.1,
130.0, 138.9, 139.5, 152.1, 161.8, 163.8, 172.3, 176.8. HRMS calcd. for (M + H)+: C30H42FN4O3
525.3241, found 525.3222.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-fluoro-
phenyl)propanamide (3h): Product 3h was obtained from resin 23, 4-fluorobenzyl bromide, cyclo-
hexanecarboxylic acid, and 2-methoxyphenylpiperazine as an amorphous light yellow solid (16.3 mg,
62% isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
1
Initial LC/MS purity 65%, tR = 9.0 min; H-NMR (CDCl3): δ 1.13–1.27 (m, 3H), 1.28–1.41 (m, 2H),
1.59–1.66 (m, 1H), 1.67–1.82 (m, 6H), 1.98–2.05 (m, 0.4H), 2.05–2.14 (m, 1H), 2.37 (t, J = 8.2 Hz,
0.4H), 2.54–2.66 (m, 2H), 2.75–2.86 (m, 3H), 2.93–3.00 (m, 1H), 3.02–3.08 (m, 1H), 3.09–3.20 (m,
3H), 3.22–3.41 (m, 3H), 3.86 (s, 3H), 4.58 (dd, J = 7.3 Hz, J = 14.8 Hz, 1H), 6.48 (brs, 1H), 6.87 (d, J
13
= 8.1 Hz, 1H), 6.91–6.99 (m, 4H), 7.00–7.07 (m, 1H), 7.12–7.20 (m, 2H), 7.49 (brs, 1H). C-NMR
(CDCl3): δ 17.6, 24.4, 25.7, 29.2, 29.7, 30.7, 37.9, 45.1, 49.5, 53.1, 54.5, 55.4, 56.2, 111.3, 115.4,
118.5, 121.1, 123.6, 130.9, 132.5, 140.3, 152.2, 160.9, 162.8, 171.3, 176.3. HRMS calcd. for (M + H)+:
C30H42FN4O3 525.3241, found 525.3244.
2-[(Benzoyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}octanamide (3i): Product 3i was
obtained from resin 23, 1-iodohexane, benzoic acid, and 2-methoxyphenylpiperazine as light yellow

Molecules 2010, 15
4975
oil (17.4 mg, 70% isolated yield) following chromatographic purification over silica gel with CH2Cl2–
1
MeOH (93:7). Initial LC/MS purity 83%, tR = 10.1 min; H-NMR (CDCl3): δ 0.81–0.89 (m, 3H),
1.21–1.41 (m, 8H), 1.71–1.83 (m, 1H), 1.84–1.98 (m, 3H), 1.99–2.06 (m, 0.4H), 2.35
(t, J = 8.2 Hz, 0.5H), 2.83 (s, 1H), 2.90–2.99 (m, 2H), 3.02–3.13 (m, 2H), 3.19–3.29 (m, 3H),
3.31–3.49 (m, 3H), 3.85 (s, 3H), 4.57 (dd, J = 7.7 Hz, J = 13.7 Hz, 1H), 6.82–6.97 (m, 3H), 7.01–7.10
(m, 1H), 7.29–7.36 (m, 1H), 7.40 (t, J = 7.5 Hz, 2H), 7.48 (t, J = 7.4 Hz, 1H), 7.86 (d, J = 7.3 Hz, 2H),
13
7.94 (brs, 1H). C-NMR (CDCl3): δ 14.0, 17.7, 22.5, 23.9, 25.8, 29.0, 30.7, 31.6, 32.6, 37.0, 48.4,
49.5, 52.8, 54.5, 55.4, 111.3, 118.7, 121.2, 124.1, 127.3, 128.6, 131.8, 133.6, 139.5, 152.2, 167.6,
173.1. HRMS calcd. for (M + H)+: C29H43N4O3 495.3335, found 495.3337.
2-[(Benzoyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3(4-methoxyphenyl)-propan-
amide (3j): Product 3j was obtained from resin 23, 4-methoxybenzyl chloride, benzoic acid, and 2-
methoxyphenylpiperazine as an amorphous light yellow solid (10.3 mg, 39% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 71%, tR
= 7.9 min; 1H-NMR (CDCl3): δ 1.72–1.87 (m, 2H), 1.96–2.09 (m, 1H), 2.37 (t, J = 8.2 Hz, 1H), 2.63–
2.73 (m, 2H), 2.79–2.91 (m, 3H), 3.10–3.20 (m, 5H), 3.31–3.39 (m, 2H), 3.76 (s, 3H), 3.86 (s, 3H),
4.74 (dd, J = 7.2 Hz, J = 14.4 Hz, 1H), 6.83 (d, J = 8.6 Hz, 2H), 6.86–6.89 (m, 1H), 6.89–6.97 (m,
2H), 7.02–7.09 (m, 2H), 7.18 (d, J = 8.6 Hz, 2H), 7.37–7.45 (m, 3H), 7.46–7.51 (m, 1H), 7.74–7.79
13
(m, 2H). C-NMR (CDCl3): δ 17.7, 24.2, 29.6, 30.7, 37.9, 49.2, 49.4, 52.9, 55.2, 55.4, 55.6, 111.3,
114.1, 118.6, 121.2, 123.7, 127.1, 128.6, 128.7, 130.4, 131.7, 133.8, 152.2, 158.6, 167.1, 171.4. HRMS
calcd. for (M + H)+: C31H29N4O4 531.2971, found 531.2951.
2-[(Benzoyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-propanamide
(3k): Product 3k was obtained from resin 23, 3-fluorobenzyl chloride, benzoic acid, and 2-
methoxyphenylpiperazine as yellow oil (12.6 mg, 49% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 75%, tR = 8.4 min; H-
NMR (CDCl3): δ 1.76–1.93 (m, 2H), 1.96–2.08 (m, 1H), 2.37 (t, J = 8.2 Hz, 1H),
2.71–2.82 (m, 2H), 2.83–2.86 (m, 1H), 2.87–2.97 (m, 2H), 3.14–3.25 (m, 5H), 3.28–3.34 (m, 1H),
3.36–3.40 (m, 1H), 3.86 (s, 3H), 4.81 (dd, J = 7.2 Hz, J = 14.6 Hz, 1H), 6.86–6.89 (m, 1H), 6.89–6.96
(m, 3H), 6.97–7.01 (m, 1H), 7.02–7.08 (m, 2H), 7.16–7.22 (m, 1H), 7.23–7.26 (m, 1H), 7.37–7.43 (m,
2H), 7.45–7.51 (m, 1H), 7.59–7.70 (m, 1H), 7.73–7.80 (m, 2H). 13C-NMR (CDCl3): δ 17.7, 24.0, 29.6,
30.7, 38.3, 48.9, 49.4, 52.9, 55.3, 55.4, 111.3, 113.8, 113.9, 118.7, 121.2, 123.9, 125.1, 127.2, 128.6,
130.1, 131.8, 133.6, 139.4, 139.5, 152.2, 161.9, 163.8, 167.2, 171.3. HRMS calcd. for (M + H)+:
C30H36FN4O3 519.2771, found 519.2782.
2-[(Benzoyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-propanamide
(3l): Product 3l was obtained from resin 23, 4-fluorobenzyl bromide, benzoic acid, and 2-methoxy-
phenylpiperazine as brownish oil (19.7 mg, 76% isolated yield) following chromatographic
purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 86%, tR = 8.3 min;
1H-NMR (CDCl3): δ 1.78–1.93 (m, 2H), 1.95–2.06 (m, 0.5H), 2.36 (t, J = 8.2 Hz, 0.5H), 2.75–2.88 (m,
3H), 2.93–3.04 (m, 2H), 3.07–3.16 (m, 2H), 3.17–3.32 (m, 5H), 3.34–3.41 (m, 1H), 3.85 (s, 3H), 4.71–
4.92 (m, 1H), 6.85–6.91 (m, 2H), 7.01–7.09 (m, 1H), 7.19–7.25 (m, 2H), 7.37 (t,

Molecules 2010, 15
4976
J = 7.6 Hz, 2H), 7.46 (t, J = 7.4 Hz, 1H), 7.77 (d, J = 7.4 Hz, 2H), 7.85 (brs, 1H). 13C-NMR (CDCl3): δ
17.6, 23.8, 29.6, 30.7, 37.5, 48.5, 49.5, 52.7, 55.4, 55.5, 111.3, 115.5, 118.7, 121.2, 124.1, 127.2,
128.5, 130.9, 131.9, 132.5, 133.4, 139.5, 152.2, 160.9, 162.8, 167.5, 171.8. HRMS calcd. for (M + H)+:
C30H36FN4O3 519.2771, found 519.2745.
2-[(Quinolin-2-oyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}octanamide (3m): Product
3m was obtained from resin 23, 1-iodohexane, quinaldic acid, and 2-methoxyphenylpiperazine as
brownish oil (18.4 mg, 67% isolated yield) following chromatographic purification over silica gel with
CH2Cl2–MeOH (95:5). Initial LC/MS purity 80%, tR = 12.1 min; 1H-NMR (CDCl3): δ 0.85 (t, J = 6.9 Hz,
3H), 1.24–1.30 (m, 4H), 1.32–1.49 (m, 4H), 1.78–1.92 (m, 1H), 1.94–2.10 (m, 3.5H), 2.37 (t, J = 8.1 Hz,
0.5H), 2.83 (s, 1H), 2.96–3.10 (m, 3H), 3.19–3.32 (m, 4H), 3.34–3.42 (m, 2H), 3.43–3.53 (m, 1H),
3.84 (s, 3H), 4.59 (dd, J = 7.3 Hz, J = 13.7 Hz, 1H), 6.82–6.96 (m, 3H), 6.99–7.09 (m, 1H), 7.57–7.71
(m, 2H), 7.76 (t, J = 8.2 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 8.21–8.34 (m, 2H),
8.61–8.82 (m, 1H). 13C-NMR (CDCl3): δ 14.0, 17.6, 22.5, 25.8, 28.9, 30.7, 31.6, 32.3, 48.2, 49.5, 52.7,
54.2, 55.4, 111.3, 118.8, 121.2, 124.1, 127.7, 128.1, 129.4, 129.9, 130.2, 137.6, 139.4, 146.5, 148.9,
152.1, 164.9, 172.4. HRMS calcd. for (M + H)+: C32H44N5O3 546.3444, found 546.3419.
2-[(Quinolin-2-oyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-methoxyphenyl)-
propanamide (3n): Product 3n was obtained from resin 23, 4-methoxybenzyl chloride, quinaldic acid,
and 2-methoxyphenylpiperazine as brownish oil (10.5 mg, 36% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 66%, tR
= 9.9 min; 1H-NMR (CDCl3): δ 1.61–1.87 (m, 2H), 1.95–2.08 (m, 1H), 2.37 (t, J = 8.1 Hz, 1H), 2.56–
2.67 (m, 2H), 2.77–2.88 (m, 3H), 3.08–3.15 (m, 2H), 3.16–3.28 (m, 3H), 3.32–3.35 (m, 1H), 3.36–3.39
(m, 1H), 3.77 (s, 3H), 3.85 (s, 3H), 4.76 (dd, J = 7.7 Hz, J = 14.4 Hz, 1H), 6.81–6.88 (m, 4H), 6.89–
6.93 (m, 1H), 6.98–7.05 (m, 1H), 7.15–7.22 (m, 1H), 7.23–7.26 (m, 2H), 7.57–7.66 (m, 1H), 7.71–7.80
(m, 1H), 7.86 (d, J = 8.1 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.27 (d, J = 8.5
13
Hz, 1H), 8.78 (d, J = 8.1 Hz, 1H). C-NMR (CDCl3): δ 17.7, 24.4, 29.6, 30.7, 37.7, 49.4, 52.9, 55.2,
55.4, 55.5, 56.1, 111.2, 114.0, 118.7, 121.1, 123.5, 127.7, 128.1, 128.8, 129.4, 129.9, 130.2, 130.5,
137.5, 146.5, 149.1, 152.2, 158.6, 164.5, 170.9. HRMS calcd. for (M + H)+: C34H40N5O4 582.3080,
found 582.3058.
2-[(Quinolin-2-oyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-
propanamide (3o): Product 3o was obtained from resin 23, 3-fluorobenzyl chloride, quinaldic acid, and
2-methoxyphenylpiperazine as brownish oil (15.3 mg, 54% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 77%, tR = 10.3 min; H-
NMR (CDCl3): δ 1.88–2.12 (m, 3H), 2.37 (t, J = 8.1 Hz, 1H), 2.84 (s, 1H), 2.93–3.04 (m, 2H), 3.19–
3.44 (m, 9H), 3.86 (s, 3H), 4.84 (dd, J = 7.0 Hz, J = 14.5 Hz, 1H), 6.85–6.98 (m, 4H), 7.02–7.10 (m,
2H), 7.13 (d, J = 7.7 Hz, 1H), 7.27–7.33 (m, 1H), 7.40–7.49 (m, 1H), 7.62 (t, J = 7.1 Hz, 1H), 7.73–
7.81 (m, 1H), 7.85 (d, J = 8.1 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.27 (d,
J = 8.4 Hz, 1H), 8.76 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3): δ 17.7, 23.7, 29.6, 30.7, 37.9, 47.8, 49.4,
52.5, 54.9, 55.4, 111.3, 114.1, 116.3, 118.5, 118.8, 121.2, 124.3, 125.2, 127.7, 128.1, 129.4, 129.9,

Molecules 2010, 15
4977
130.2, 137.5, 139.3, 146.5, 148.8, 152.1, 161.9, 162.7, 163.8, 164.8, 171.3. HRMS calcd. for (M + H)+:
C33H37FN5O3 570.2880, found 570.2853.
2-[(Quinolin-2-oyl)amino]-N-{[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-
propanamide (3p): Product 3p was obtained from resin 23, 4-fluorobenzyl bromide, quinaldic acid,
and 2-methoxyphenylpiperazine as brownish oil (22.1 mg, 78% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 85%, tR
1
= 10.2 min; H-NMR (CDCl3): δ 1.92–2.08 (m, 2.5H), 2.32–2.42 (m, 0.5H), 2.83 (s, 1H), 2.93–3.04
(m, 2H), 3.18–3.44 (m, 10H), 3.85 (s, 3H), 4.83 (dd, J = 7.3 Hz, J = 14.7 Hz, 1H), 6.84–6.95 (m, 3H),
6.96–7.02 (m, 2H), 7.03–7.09 (m, 1H), 7.28–7.36 (m, 2H), 7.47–7.56 (m, 1H), 7.61 (t, J = 7.4 Hz, 1H),
7.76 (t, J = 7.1 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H),
13
8.26 (d, J = 8.5 Hz, 1H), 8.74 (d, J = 7.8 Hz, 1H). C-NMR (CDCl3): δ 17.7, 23.6, 29.6, 30.7, 36.5,
37.5, 47.7, 49.4, 52.5, 54.6, 55.2, 55.4, 111.3, 115.4, 118.6, 118.9, 121.2, 124.3, 127.7, 128.1, 129.4,
129.9, 130.2, 131.0, 132.5, 139.1, 146.5, 148.9, 152.1, 160.9, 162.4, 162.9, 164.7, 171.5. HRMS calcd.
for (M + H)+: C33H37FN5O3 570.2880, found 570.2870.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}octanamide (3q):
Product 3q was obtained from resin 23, 1-iodohexane, cyclopropanecarboxylic acid, and 3-chloro-
phenylpiperazine as brownish oil (11.2 mg, 48% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 68%, tR = 9.7 min; H-
NMR (CDCl3): δ 0.66–0.79 (m, 2H), 0.81–0.97 (m, 5H), 1.18–1.37 (m, 8.6H), 1.38–1.52 (m, 1H),
1.56–1.70 (m, 1H), 1.76–1.84 (m, 1H), 1.84–1.93 (m, 1.6H), 1.96–2.08 (m, 0.4H), 2.37 (t,
J = 8.1 Hz, 0.4H), 2.72–2.83 (m, 2H), 2.84 (s, 1H), 2.87–3.01 (m, 3H), 3.27–3.44 (m, 6H), 4.34 (dd,
J = 7.5 Hz, J = 14.1 Hz, 1H), 6.62 (brs, 1H), 6.75–6.81 (m, 1H), 6.83–6.90 (m, 2H), 7.15–7.22 (m,
13
1H), 7.39–7.57 (m, 1H). C-NMR (CDCl3): δ 7.4, 7.5, 14.0, 14.6, 17.7, 22.5, 24.5, 25.6, 29.0, 31.6,
32.6, 47.7, 49.5, 52.4, 53.9, 55.7, 114.4, 116.5, 120.5, 130.3, 135.1, 151.4, 172.7, 174.1. HRMS calcd.
for (M + H)+: C25H40ClN4O2 463.2840, found 463.2841.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3(4-methoxy-
phenyl)propanamide (3r): Product 3r was obtained from resin 23, 4-methoxybenzyl chloride,
cyclopropanecarboxylic acid, and 3-chlorophenyl piperazine as yellow oil (10.2 mg, 41% isolated
yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (92:8). Initial
1
LC/MS purity 60%, tR = 7.7 min; H-NMR (CDCl3): δ 0.67–0.79 (m, 2H), 0.85–0.94 (m, 2H),
1.39–1.44 (m, 1H), 1.71–1.83 (m, 2H), 1.97–2.08 (m, 1H), 2.37 (t, J = 8.2 Hz, 1H), 2.57–2.64 (m, 2H),
2.75–2.82 (m, 2H), 2.83–2.85 (m, 1H), 2.97–3.01 (m, 1H), 3.24–3.30 (m, 5H), 3.36–3.41 (m, 1H), 3.77
(s, 3H), 4.45–4.68 (m, 1H), 6.64 (brs, 1H), 6.77 (d, J = 7.4 Hz, 1H), 6.82 (d, J = 8.4 Hz, 2H), 6.87 (d,
J = 7.0 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 7.18 (t, J = 8.3 Hz, 1H). 13C-NMR (CDCl3): δ 7.4, 7.5, 13.5,
14.6, 17.7, 29.6, 30.7, 37.7, 47.7, 49.5, 52.3, 55.3, 113.9, 114.4, 116.4, 120.4, 128.8, 130.3, 130.4,
135.1, 151.4, 158.5, 171.6, 173.8. HRMS calcd. for (M + H)+: C27H36ClN4O3 499.2476, found
499.2467.

Molecules 2010, 15
4978
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-
propanamide (3s): Product 3s was obtained from resin 23, 3-fluorobenzyl chloride, cyclo-
propanecarboxylic acid, and 3-chlorophenylpiperazine as light yellow oil (8.0 mg, 33% isolated yield)
following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS
1
purity 57%, tR = 8.2 min; H-NMR (CDCl3): δ 0.67–0.81 (m, 2H), 0.86–0.96 (m, 2H), 1.37–1.47 (m,
1H), 1.77 (brs, 2H), 2.57–2.89 (m, 5H), 3.04–3.12 (m, 2H), 3.22–3.41 (m, 7H), 4.47–4.72 (m, 1H),
6.55 (brs, 1H), 6.74–6.81 (m, 1H), 6.85–6.89 (m, 2H), 6.91–6.96 (m, 2H), 7.00 (d, J = 7.7 Hz, 1H),
7.19 (t, J = 8.4 Hz, 2H), 7.23–7.26 (m, 1H). 13C-NMR (CDCl3): δ 7.5, 7.6, 14.6, 24.4, 38.3, 47.9, 52.5,
54.9, 56.0, 113.7, 114.3, 116.2, 116.4, 120.3, 125.2, 130.0, 130.2, 135.1, 139.5, 151.5, 161.8, 163.8,
171.4, 173.8. HRMS calcd. for (M + H)+: C26H33ClFN4O2 487.2276, found 487.2299.
2-[(Cyclopropanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-
propanamide (3t): Product 3t was obtained from resin 23, 4-fluorobenzyl bromide, cyclo-
propanecarboxylic acid, and 3-chlorophenylpiperazine as brown oil (9.9 mg, 41% isolated yield)
following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS
purity 73%, tR = 8.1 min; 1H-NMR (CDCl3): δ 0.67–0.78 (m, 2H), 0.83–0.94 (m, 2H),
1.37–1.47 (m, 1H), 1.69–1.85 (m, 2H), 2.58–2.73 (m, 2H), 2.75–2.94 (m, 4H), 2.98–3.07 (m, 2H),
3.21–3.39 (m, 6H), 4.58 (dd, J = 7.3 Hz, J = 14.7 Hz, 1H), 6.63 (brs, 1H), 6.74–6.79 (m, 1H),
13
6.84–6.91 (m, 2H), 6.94–7.01 (m, 2H), 7.10–7.26 (m, 4H). C-NMR (CDCl3): δ 7.4, 7.6, 14.6, 24.3,
37.7, 47.6, 52.3, 55.1, 55.6, 114.5, 115.4, 116.5, 120.6, 130.3, 130.9, 132.6, 135.1, 151.3, 160.9, 162.8,
171.4, 173.9. HRMS calcd. for (M + H)+: C26H33ClFN4O2 487.2276, found 487.2292.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}octanamide
(3u):
Product 3u was obtained from resin 23, 1-iodohexane, cyclohexanecarboxylic acid, and 3-
chlorophenyl piperazine as brown oil (10.9 mg, 43% isolated yield) following chromatographic
purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 66%, tR = 12.2 min;
1H-NMR (CDCl3): δ 0.76–0.92 (m, 3H), 1.16–1.33 (m, 11H), 1.35–1.47 (m, 2H), 1.55–1.69 (m, 2H),
1.71–1.95 (m, 7H), 1.97–2.07 (m, 0.5H), 2.09–2.22 (m, 1H), 2.38 (t, J = 8.0 Hz, 0.5H), 2.78–2.86 (m,
2H), 2.89–3.04 (m, 3H), 3.25–3.45 (m, 6H), 4.15–4.44 (m, 1H), 6.38 (brs, 1H), 6.78 (d, J = 8.1 Hz,
1H), 6.82–6.93 (m, 2H), 7.18 (t, J = 8.3 Hz, 1H), 7.53 (brs, 1H). 13C-NMR (CDCl3): δ 14.0, 17.7, 22.5,
25.5, 25.7, 28.9, 29.3, 29.8, 31.6, 32.4, 37.3, 45.2, 47.6, 49.5, 52.4, 53.5, 55.5, 114.5, 116.6, 120.6,
130.3, 135.1, 151.3, 172.8, 176.7. HRMS calcd. for (M + H)+: C28H46ClN4O2 505.3309, found
505.3318.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3(4-methoxyphenyl)-
propanamide (3v): Product 3v was obtained from resin 23, 4-methoxybenzyl chloride, cyclo-
hexanecarboxylic acid, and 3-chlorophenylpiperazine as an amorphous off-white solid (6.9 mg, 26%
isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
Initial LC/MS purity 55%, tR = 10.1 min; 1H-NMR (CDCl3): δ 1.17–1.26 (m, 3H), 1.31–1.41 (m, 2H),
1.61–1.67 (m, 1H), 1.71–1.84 (m, 7H), 1.98–2.05 (m, 0.6H), 2.07–2.15 (m, 1H), 2.37 (t, J = 8.2 Hz,
0.6H), 2.59–2.71 (m, 3H), 2.84 (s, 1H), 2.98 (d, J = 6.7 Hz, 2H), 3.24–3.35 (m, 6H), 3.78 (s, 3H), 4.51
(dd, J = 7.1 Hz, J = 14.3 Hz, 1H), 6.22 (brs, 1H), 6.75–6.79 (m, 1H), 6.82 (d, J = 8.5 Hz, 2H),

Molecules 2010, 15
4979
6.86–6.89 (m, 2H), 6.96–7.07 (m, 1H), 7.12 (d, J = 8.6 Hz, 2H), 7.16–7.22 (m, 1H). 13C-NMR
(CDCl3): δ 17.7, 24.4, 25.5, 25.7, 29.3, 29.7, 30.7, 37.7, 45.1, 49.4, 52.4, 54.8, 55.3, 113.9, 114.4,
116.4, 120.4, 128.8, 130.2, 130.4, 135.1, 151.4, 158.5, 171.5, 176.2. HRMS calcd. for (M + H)+:
C30H42ClN4O3 541.2945, found 541.2943.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(3-chloroyphenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-
propanamide (3w): Product 3w was obtained from resin 23, 3-fluorobenzyl chloride, cyclo-
hexanecarboxylic acid, and 3-chlorophenylpiperazine as an amorphous light yellow solid (8.5 mg,
32% isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (94:6).
Initial LC/MS purity 54%, tR = 10.6 min; 1H-NMR (CDCl3): δ 1.17–1.28 (m, 3H), 1.29–1.41 (m, 2H),
1.62–1.81 (m, 7H), 1.99–2.14 (m, 2H), 2.37 (t, J = 8.0 Hz, 1H), 2.49–2.59 (m, 2H), 2.62–2.73 (m, 3H),
2.84 (s, 1H), 2.96–3.09 (m, 2H), 3.18–3.25 (m, 3H), 3.27–3.31 (m, 1H), 3.38
(t, J = 7.0 Hz, 1H), 4.48–4.64 (m, 1H), 6.32 (brs, 1H), 6.77 (d, J = 8.2 Hz, 1H), 6.83–6.89 (m, 2H),
13
6.90–6.96 (m, 2H), 6.98 (d, J = 7.6 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.21–7.26 (m, 1H). C-NMR
(CDCl3): δ 17.7, 24.7, 25.5, 25.6, 29.3, 29.7, 30.7, 38.3, 45.1, 48.1, 49.5, 52.6, 54.4, 56.2, 113.8, 113.9,
114.2, 116.2, 116.3, 120.0, 125.1, 130.2, 139.3, 151.7, 161.8, 163.8, 170.9, 176.2. HRMS calcd. for (M
+ H)+: C29H39ClFN4O2 529.2746, found 529.2736.
2-[(Cyclohexanecarbonyl)amino]-N-{[4-(3-chloroyphenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-
propanamide (3x): Product 3x was obtained from resin 23, 4-fluorobenzyl bromide, cyclo-
hexanecarboxylic acid, and 3-chlorophenylpiperazine as an amorphous yellow solid (11.7 mg, 44%
isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH (93:7).
Initial LC/MS purity 72%, tR = 10.5 min; 1H-NMR (CDCl3): δ 1.11–1.28 (m, 3H), 1.29–1.41 (m, 2H),
1.60–1.67 (m, 1H), 1.69–1.82 (m, 5H), 1.97–2.04 (m, 0.5H), 2.05–2.14 (m, 1H), 2.37 (t, J = 8.2 Hz,
0.5H), 2.59–2.73 (m, 2H), 2.75–2.92 (m, 4H), 2.97 (dd, J = 7.1 Hz, J = 13.7 Hz, 1H), 3.06 (dd,
J = 7.2 Hz, J = 13.6 Hz, 1H), 3.23–3.35 (m, 5H), 3.35–3.40 (m, 1H), 4.55 (dd, J = 7.1 Hz, J = 14.4 Hz,
1H), 6.36 (d, J = 6.0 Hz, 1H), 6.77 (d, J = 8.3 Hz, 1H), 6.83–6.90 (m, 2H), 6.96 (t, J = 8.5 Hz, 2H),
13
7.11–7.22 (m, 3H), 7.24–7.26 (m, 1H). C-NMR (CDCl3): δ 17.7, 24.4, 25.7, 29.2, 29.7, 30.7, 37.7,
45.1, 47.7, 49.5, 52.4, 54.6, 55.6, 114.4, 115.3, 116.5, 120.5, 130.3, 130.9, 132.6, 135.1, 151.3, 160.9,
162.8, 171.4, 176.4. HRMS calcd. for (M + H)+: C29H39ClFN4O2 529.2746, found 529.2741.
2-[(Benzoyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}octanamide (3y): Product 3y was
obtained from resin 23, 1-iodohexane, benzoic acid, and 3-chlorophenylpiperazine as brown oil (10.3
mg, 41% isolated yield) following chromatographic purification over silica gel with CH2Cl2–MeOH
1
(94:6). Initial LC/MS purity 68%, tR = 11.5 min; H-NMR (CDCl3): δ 0.78–0.89 (m, 3H), 1.10–1.41
(m, 9H), 1.68–1.81 (m, 1H), 1.84–1.94 (m, 2H), 1.97–2.08 (m, 0.4H), 2.37 (t, J = 8.1 Hz, 0.4H),
2.70–2.80 (m, 2H), 2.81–2.93 (m, 3H), 3.23–3.46 (m, 6H), 4.38–4.69 (m, 1H), 6.76 (d,
J = 8.6 Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 7.05 (brs, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.42 (t, J = 7.5 Hz,
2H), 7.49 (t, J = 7.3 Hz, 1H), 7.59 (brs, 1H), 7.83 (d, J = 7.4 Hz, 2H). 13C-NMR (CDCl3): δ 14.0, 17.7,
22.5,, 29.0, 31.6, 32.7, 37.8, 47.7, 52.5, 54.2, 55.9, 114.4, 116.4, 120.4, 127.2, 128.6, 130.2, 131.8,
133.7, 135.1, 151.4, 167.4, 172.4. HRMS calcd. for (M + H)+: C28H40ClN4O2 499.2840, found
499.2840.

Molecules 2010, 15
4980
2-[(Benzoyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3(4-methoxyphenyl)-propanamide
(3z): Product 3z was obtained from resin 23, 4-methoxybenzyl chloride, benzoic acid, and 3-
chlorophenyl piperazine as an amorphous white solid (5.2 mg, 19% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 59%,
tR = 9.4 min; 1H -MR (CDCl3): δ 1.64–1.75 (m, 2H), 2.43–2.73 (m, 6H), 3.05–3.21 (m, 6H), 3.26–3.39
(m, 2H), 3.78 (s, 3H), 4.69 (dd, J = 7.5 Hz, J = 13.7 Hz, 1H), 6.74 (d, J = 7.4 Hz, 1H),
6.79–6.87 (m, 4H), 6.92 (d, J = 6.0 Hz, 1H), 7.08 (brs, 1H), 7.14–7.21 (m, 3H), 7.39 (t, J = 7.6 Hz,
13
2H), 7.48 (t, J = 7.4 Hz, 1H), 7.74 (d, J = 7.3 Hz, 2H). C-NMR (CDCl3): δ 24.6, 37.9, 38.5, 48.2,
52.7, 55.3, 55.6, 56.6, 114.1, 116.1, 119.9, 127.1, 128.6, 128.7, 130.1, 130.4, 131.8, 133.7, 135.0,
151.7, 158.7, 167.0, 170.9. HRMS calcd. for (M + H)+: C30H36ClN4O3 535.2476, found 535.2470.
2-[(Benzoyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-propanamide
(3aa): Product 3aa was obtained from resin 23, 3-fluorobenzyl chloride, benzoic acid, and 3-
chlorophenylpiperazine as light yellow oil (9.2 mg, 35% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 61%, tR = 9.9 min; H-
NMR (CDCl3): δ 1.61–1.77 (m, 2H), 1.96–2.07 (m, 1H), 2.37 (t, J = 8.1 Hz, 1H), 2.49–2.54 (m, 1H),
2.55–2.63 (m, 2H), 2.64–2.69 (m, 1H), 2.84 (s, 1H), 3.14–3.19 (m, 4H), 3.25–3.40 (m, 3H), 4.64–4.85
(m, 1H), 6.75 (d, J = 7.6 Hz, 1H), 6.85 (d, J = 7.4 Hz, 2H), 6.91–7.01 (m, 2H), 7.02–7.09 (m, 2H)),
7.14–7.21 (m, 1H), 7.22–7.26 (m, 1H), 7.29–7.36 (m, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.46–7.52 (m, 1H),
7.75 (d, J = 7.8 Hz, 2H). 13C-NMR (CDCl3): δ 17.7, 14.5, 19.6, 30.7, 38.4, 48.1, 49.5, 52.6, 55.3, 56.4,
113.9, 114.0, 114.2, 116.2, 116.4, 119.9, 125.1, 127.1, 128.6, 130.1, 131.9, 133.5, 135.0, 139.4, 151.7,
161.9, 163.8, 167.2, 170.8. HRMS calcd. for (M + H)+: C29H33ClFN4O2 523.2276, found 523.2283.
2-[(Benzoyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-propanamide
(3ab): Product 3ab was obtained from resin 23, 4-fluorobenzyl bromide, benzoic acid, and 3-chloro-
phenylpiperazine as an amorphous light yellow solid (14.2 mg, 54% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 73%, tR
1
= 9.8 min; H-NMR (CD3OD/CDCl3): δ 1.74–1.85 (m, 2H), 1.97–2.07 (m, 1H), 2.37 (t, J = 8.1 Hz,
1H), 2.63–2.76 (m, 2H), 2.82–2.92 (m, 3H), 3.09 (dd, J = 7.2 Hz, J = 13.5 Hz, 1H), 3.16 (dd,
J = 7.4 Hz, J = 13.7 Hz, 1H), 3.23–3.34 (m, 5H), 4.63–4.84 (m, 1H), 6.72–6.81 (m, 1H),
6.82–6.92 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 7.09–7.26 (m, 3H), 7.41 (t, J = 7.6 Hz, 2H), 7.47–7.53 (m,
13
1H), 7.76 (d, J = 7.8 Hz, 2H). C-NMR (CD3OD/CDCl3): δ 17.6, 24.3, 29.6, 30.7, 37.5, 47.5, 52.3,
55.4, 114.5, 115.4, 115.5, 116.6, 120.6, 127.2, 128.6, 130.3, 130.8, 130.9, 132.0, 132.4, 133.3, 135.1,
151.2, 160.9, 162.9, 167.6, 168.8. HRMS calcd. for (M + H)+: C29H33ClFN4O2 523.2276, found
523.2252.
2-[(Quinolin-2-oyl)amino]-N-{[4-(3-chloroyphenyl)-piperazin-1-yl]propyl}octanamide (3ac): Product
3ac was obtained from resin 23, 1-iodohexane, quinaldic acid, and 3-chlorophenylpiperazine as brown
oil (12.4 mg, 45% isolated yield) following chromatographic purification over silica gel with CH2Cl2–
MeOH (95:5). Initial LC/MS purity 72%, tR = 13.3 min; 1H-NMR (CDCl3): δ 0.86 (t, J = 6.9 Hz, 3H),
1.24–1.32 (m, 5H), 1.34–1.51 (m, 4H), 1.79–1.93 (m, 1H), 1.96–2.09 (m, 3H), 2.84 (s, 1H), 2.92–3.19
(m, 4H), 3.33–3.48 (m, 6H), 4.53 (dd, J = 7.6 Hz, 13.7 Hz, 1H), 6.72 (dd, J = 2.1 Hz, J = 8.3 Hz, 1H),

Molecules 2010, 15
4981
6.78–6.84 (m, 1H), 6.89 (d, J = 7.9 Hz, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.39 (brs, 1H), 7.58–7.66 (m,
1H), 7.72–7.81 (m, 1H), 7.86 (d, J = 8.1 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H),
13
8.28 (d, J = 8.5 Hz, 1H), 8.63 (d, J = 7.5 Hz, 1H). C-NMR (CDCl3): δ 14.0, 17.7, 22.5, 25.9, 28.9,
31.6, 32.1, 36.9, 46.9, 52.1, 54.3, 55.2, 114.6, 116.7, 118.6, 120.9, 127.7, 128.2, 129.4, 129.9, 130.3,
135.1, 137.6, 146.5, 148.9, 150.9, 164.9, 172.4. HRMS calcd. for (M + H)+: C31H41ClN5O2 550.2949,
found 550.2936.
2-[(Quinolin-2-oyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(4-methoxyphenyl)-
propanamide (3ad): Product 3ad was obtained from resin 23, 4-methoxybenzyl chloride, quinaldic
acid, and 3-chlorophenylpiperazine as brown oil (8.0 mg, 27% isolated yield) following
chromatographic purification over silica gel with CH2Cl2–MeOH (94:6). Initial LC/MS purity 58%, tR
= 11.3 min; 1H-NMR (CDCl3): δ 1.62–1.73 (m, 2H), 1.97–2.06 (m, 1H), 2.37 (t, J = 8.2 Hz, 1H), 2.42–
2.47 (m, 1H), 2.48–2.59 (m, 3H), 2.84 (s, 1H), 2.97–3.07 (m, 3H), 3.17 (dd, J = 7.6 Hz, J = 13.7 Hz,
1H), 3.26 (dd, J = 5.8 Hz, J = 13.8 Hz, 1H), 3.32–3.39 (m, 2H), 3.78 (s, 3H), 4.76 (dd, J = 7.5 Hz,
J = 14.0 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.69 (brs, 1H), 6.79 (d, J = 7.4 Hz, 1H), 6.86 (d, J = 8.4 Hz,
2H), 7.04–7.14 (m, 2H), 7.22–7.26 (m, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.69–7.77 (m, 1H), 7.84 (d,
13
J = 8.2 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 8.16–8.28 (m, 2H), 8.75 (d, J = 7.9 Hz, 1H). C-NMR
(CDCl3): δ 17.7, 24.7, 29.6, 30.7, 37.5, 47.9, 49.5, 52.8, 55.4, 113.8, 114.1, 115.7, 118.7, 127.7, 128.2,
128.8, 129.4, 129.8, 130.0, 130.2, 130.6, 134.9, 137.6, 146.4, 148.9, 156.6, 158.7, 164.6, 170.7. HRMS
calcd. for (M + H)+: C33H37ClN5O3 586.2585, found 586.2600.
2-[(Quinolin-2-oyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(3-fluorophenyl)-
propanamide (3ae): Product 3ae was obtained from resin 23, 3-fluorobenzyl chloride, quinaldic acid,
and 3-chlorophenylpiperazine as brown oil (9.4 mg, 33% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (95:5). Initial LC/MS purity 59%, tR = 11.6 min; H-
NMR (CDCl3): δ 1.58–1.70 (m, 2H), 1.95–2.08 (m, 1H), 2.35–2.42 (m, 2H), 2.43–2.50 (m, 3H), 2.84
(s, 1H), 2.94–3.03 (m, 3H), 3.21–3.27 (m, 1H), 3.29–3.40 (m, 3H), 4.81 (dd, J = 7.9 Hz, J = 14.0 Hz,
1H), 6.92–7.00 (m, 1H), 7.04–7.13 (m, 3H), 7.17–7.22 (m, 1H), 7.27–7.32 (m, 1H), 7.57–7.64 (m, 1H),
7.71–7.77 (m, 1H), 7.84 (d, J = 8.2 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 8.15–8.28 (m, 2H), 8.73 (d,
J = 8.4 Hz, 1H). 13C-NMR (CDCl3): δ 17.7, 24.7, 29.6, 30.7, 38.1, 39.2, 48.1, 52.9, 54.9, 57.0, 113.6,
113.9, 114.0, 115.5, 116.4, 116.6, 118.6, 119.3, 125.4, 127.7, 128.2, 129.4, 129.8, 129.9, 130.3, 134.9,
137.6, 139.4, 146.4, 148.8, 151.7, 161.9, 163.9, 164.6, 170.2. HRMS calcd. for (M + H)+:
C32H34ClFN5O2 574.2385, found 574.2402.
2-[(Quinolin-2-oyl)amino]-N-{[4-(3-chlorophenyl)-piperazin-1-yl]propyl}-3-(4-fluorophenyl)-
propanamide (3af). Product 3af was obtained from resin 23, 4-fluorobenzyl bromide, quinaldic acid,
and 3-chlorophenylpiperazine as brown oil (15.5 mg, 54% isolated yield) following chromatographic
1
purification over silica gel with CH2Cl2–MeOH (93:7). Initial LC/MS purity 72%, tR = 11.5 min; H-
NMR (CDCl3): δ 1.84–1.98 (m, 2H), 1.98–2.05 (m, 0.5H), 2.37 (t, J = 8.1 Hz, 0.5H), 2.79–3.17 (m,
5H), 3.20–3.44 (m, 8H), 4.79 (dd, J = 7.2 Hz, J = 14.7 Hz, 1H), 6.71 (dd, J = 2.1 Hz, J = 8.3 Hz, 1H),
6.78–6.84 (m, 1H), 6.89 (dd, J = 1.1 Hz, J = 7.9 Hz, 1H), 6.96–7.04 (m, 2H), 7.17 (t, J = 8.1 Hz, 1H),
7.27–7.40 (m, 3H), 7.57–7.66 (m, 1H), 7.72–7.81 (m, 1H), 7.85 (d, J = 8.1 Hz, 1H), 8.07 (d,

Molecules 2010, 15
4982
J = 8.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.72 (d, J = 7.8 Hz, 1H). 13C-NMR
(CDCl3): δ 17.7, 23.9, 29.6, 30.7, 37.1, 37.4, 46.9, 49.4, 52.0, 55.2, 114.5, 115.4, 115.6, 116.7, 118.5,
120.9, 127.7, 128.2, 129.4, 129.8, 130.3, 131.0, 132.4, 135.1, 137.6, 146.5, 148.8, 150.8, 160.9, 162.9,
164.8, 171.2. HRMS calcd. for (M + H)+: C32H34ClFN5O2 574.2385, found 574.2376.
Acknowledgements
We gratefully acknowledge the National Institutes of Health (R01 GM028193), The National
Science Foundation (MRI CHE-0619254), The Camille and Henry Dreyfus Foundation, and the
Central Indiana Community Foundation for their financial support. This study was partially supported
by the Polish Ministry of Science and Higher Education (MNiSW), Grant No. N N405 378437.
References and Notes
1. Scott, W.L.; O’Donnell, M.J. Distributed drug discovery, part 1: Linking academia and
combinatorial chemistry to find drug leads for developing world diseases. J. Comb. Chem. 2009,
11, 3-13.
2. Scott, W.L.; Alsina, J.; Audu, C.O.; Babaev, E.; Cook, L.; Dage, J.L.; Goodwin, L.A.; Martynow,
J.G.; Matosiuk, D.; Royo, M.; Smith, J.G.; Strong, A.T.; Wickizer, K.; Woerly, E.M.; Zhou, Z.;
O’Donnell, M.J. Distributed drug discovery, part 2: Global rehearsal of alkylating agents for the
synthesis of resin-bound unnatural amino acids and virtual D3 catalog construction. J. Comb.
Chem. 2009, 11, 14-33.
3. Scott, W.L.; Audu, C.O.; Dage, J.L.; Goodwin, L.A.; Martynow, J.G.; Platt, L.K; Smith, J.G.;
Strong, A.T.; Wickizer, K.; Woerly, E.M.; O’Donnell, M.J. Distributed drug discovery, part 3:
Using D3 methodology to synthesize analogs of an anti-melanoma compound. J. Comb. Chem.
2009, 11, 34-43.
4. O'Donnell, M.J.; Zhou, C.; Scott, W.L. Solid-phase unnatural peptide synthesis (UPS). J. Am.
Chem. Soc. 1996, 118, 6070-6071.
5. Scott, W.L.; Martynow, J.G.; Huffman, J.C.; O’Donnell, M.J. Solid-phase synthesis of multiple
classes of peptidomimetics from versatile resin-bound aldehyde intermediates. J. Am. Chem. Soc.
2007, 129, 7077-7088.
6. Scott, W.L.; Zhou, Z.; Martynow, J.G.; O’Donnell, M.J. Solid-phase synthesis of amino- and
carboxyl-functionalized unnatural α-amino acid amides. Org. Lett. 2009, 11, 3558-3561.
7. Perucca, E.; Yasothan, U.; Clincke, G.; Kirkpatrick, P. Lacosamide. Nat. Rev. Drug Discovery
2008, 7, 973-974.
8. Zajdel, P.; Subra, G.; Bojarski, A.J.; Duszyńska, B.; Tatarczyńska, E.; Nikiforuk, A.; Chojnacka-
Wójcik, E.; Pawłowski, M.; Martinez, J. Novel class of arylpiperazines containing N-acylated
amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological
evaluation. Bioorg. Med. Chem. 2007, 15, 2907-2919.
9. Zajdel, P.; Subra, G.; Bojarski, A.J.; Duszyńska, B.; Pawłowski, M.; Martinez, J. A new class of
arylpiperazine derivatives: the library synthesis on SynPhase lanterns and biological evaluation on
serotonin 5-HT1A and 5-HT2A receptors. J. Comb. Chem. 2004, 6, 761-767.

Molecules 2010, 15
4983
10. Zajdel, P.; Subra, G.; Bojarski, A.J.; Duszyńska, B.; Pawłowski, M.; Martinez, J. Arylpiperazines
with N-acylated amino acids as 5-HT1A receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16,
3406-3410.
11. Zajdel, P.; Subra, G.; Pawłowski, M.; Martinez J. Solid-phase synthesis of aryl-alkylamine
derivatives using protected aminoalcohol building blocks on SynPhaseTM lanterns. QSAR Comb.
Sci. 2007, 26, 215-219.
12. Olsen, C.A.; Franzyk, H.; Jaroszewski, J.W. N-Alkylation reactions and indirect formation of
amino functionalities in solid-phase synthesis. Synthesis 2005, 2631-2653.
13. Kupihár, Z.; Schmél; Z.; Kele, Z.; Penke, B.; Kovács, L. Synthesis and application of a novel,
crystalline phosphoramidite monomer with thiol terminus, suitable for the synthesis of DNA
conjugates. Bioorg. Med. Chem. 2001, 9, 1241-1247.
14. Available from Leads Metal Products, PO Box 441186, Indianapolis, IN 46244-1186
(larry@leadsmetal.com).
15. Vojkovsky, T. A negative chloranil test indicates completion of coupling (absence of starting
amine). Pept. Res. 1995, 8, 236-237.
Sample Availability: Contact the authors.
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).